| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib) |
| 06 Jul 2026 |
8-K: Creation of a Direct Financial Obligation; Other Events
NEW YORK, July 6, 2026 – Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full the... |
| 30 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. |
| 27 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Nuvation Bio Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of 389,931,796 shares of the Company’s common stock (consisting of 289,931,796 shares of Class A Comm... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition
Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Forward-looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Sec... |
| 26 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
DRIVEN BY SCIENCE FOCUSED ON LIFE November 2025 Exhibit 99.1 |
| 17 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 DRIVEN BY SCIENCE FOCUSED ON LIFE November 2025 |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Successfully started 204 patients on IBTROZITM (taletrectinib) in the third quarter of 2025 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 |
| 11 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Forward-looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Sec... |
| 23 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2025, Nuvation Bio Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of 281,460,830 shares of the Company’s common stock (consisting of 280,460,830 shares of Class A Comm... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23... |
| 25 Mar 2025 |
8-K: Entry into a Material Definitive Agreement
On March 21, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Life Science (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug product (t... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC); Prescription Drug User Fee Act (PDUFA... |
| 05 Mar 2025 |
8-K: Entry into a Material Definitive Agreement
On March 3, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Laboratories (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug substance (... |
| 04 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On March 3, 2025 (the “Closing Date”), Nuvation Bio Inc. (the “Company”) entered into a $100.0 million senior secured loan agreement (the “Loan Agreement”), with Sagard Holdings Manager LP (“Sagard”) as administrative agent, and the lend... |
| 12 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals including China’s National Medica... |
Loading...